[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368965-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368965-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","assessing-the-oncological-safety-of-glucagon-like-peptide-1-receptor-agonists-a-systematic-review-and-meta-analysis","Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists - A Systematic Review and Meta-Analysis","","Glucagon-like peptide-1 (GLP-1) receptor agonists support type 2 diabetes treatment and weight loss, but concerns have emerged about possible links with pancreatic and thyroid cancers. This systematic review and meta-analysis assessed cancer incidence in obese/overweight adults, including patients with diabetes and non-diabetic participants. Searches in PubMed, Scopus, and Cochrane identified nine RCTs (1,882 studies; 9,078 participants). Results showed weight and HbA1c improvements, while neoplasm incidences varied, with liraglutide reporting a significant cancer odds ratio.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/assessing-the-oncological-safety-of-glucagon-like-peptide-1-receptor-agonists-a-systematic-review-and-meta-analysis/368965/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/assessing-the-oncological-safety-of-glucagon-like-peptide-1-receptor-agonists-a-systematic-review-and-meta-analysis/368965.png","ImageObject",300,407,{"name":42,"@type":43},"PakDamar76","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the document’s main research question about GLP-1 receptor agonists?","Question",{"text":63,"@type":64},"It evaluates whether GLP-1 receptor agonists are associated with cancer incidence, with attention to pancreatic and thyroid cancers, in obese/overweight populations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were studies selected for the systematic review and meta-analysis?",{"text":68,"@type":64},"The review used a systematic search of PubMed, Scopus, and Cochrane to identify randomized clinical trials, followed by data extraction and risk-of-bias assessment using the Risk of Bias 2 tool.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the included randomized trials show regarding cancer risk and metabolic outcomes?",{"text":72,"@type":64},"Across nine included RCTs, GLP-1 receptor agonists reduced body weight and HbA1c in non-diabetic overweight/obese participants, but neoplasm incidences varied by agent; liraglutide showed a statistically significant odds ratio for cancer risk.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368965,1790470766,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review began 10/15/2025  \nReview ended 10/29/2025  \nPublished 11/04/2025  \n© Copyright 2025  \nJaradat et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited.  \nDOI: 10.7759/cureus.96071  \nOpen Access Review Article  \nAssessing the Oncological Safety of GlucagonLike Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis  \nJaber H. Jaradat 1, Rawan I. Al-Ahmad 2 , Maha Al Jaghbeer 3 , Ahlam A. Abdelaziz 3, Nour M. Abu Afifeh 4 , Ghazi Abu Afifeh 5 , Asad Rao 6, Amjad Alzoubi 7, Abdulqadir J. Nashwan 8  \n1. School of Medicine, Mutah University, Al Karak, JOR 2. Faculty of Medicine, Yarmouk University, Irbid, JOR 3. Administrative and Financial Affairs, Jordan Food and Drug Administration, Amman, JOR 4. Faculty of Medicine, University of Jordan, Amman, JOR 5. Internal Medicine, University of Jordan, Amman, JOR 6. Medicine, Dow University of Health Sciences, Karachi, PAK 7. Faculty of Medicine, Jordan University of Science and Technology, Irbid, JOR 8. Nursing and Midwifery Research, Hamad Medical Corporation, Doha, QAT  \nCorresponding author: Abdulqadir J. Nashwan, anashwan@hamad.qa  \nAbstract  \nGlucagon-like peptide-1 (GLP-1) receptor agonists are essential for treating type 2 diabetes and promoting weight loss. Despite their therapeutic benefits, concerns have arisen regarding their potential association with pancreatic and thyroid cancers. This systematic review and meta-analysis examined the correlation between GLP-1 receptor agonists and cancer incidence in obese/overweight individuals, including both patients with diabetes and overweight/obese non-diabetic participants. A systematic search of PubMed, Scopus, and Cochrane databases identified randomized clinical trials (RCTs) for inclusion. Data extraction and risk of bias assessment followed rigorous methodologies, using the Risk of Bias 2 tool. Of the 1,882 identified studies, nine RCTs (9,078 participants) met the inclusion criteria. The studies varied in duration (12-104 weeks) and demographics, with a mean participant age of 46 .9 years and a mean body mass index of 36.9 kg/m². In non-diabetic overweight/obese participants, GLP-1 receptor agonists significantly reduced body weight and HbA 1c levels compared to placebo. However, varying incidences of neoplasms were observed, with liraglutide showing a statistically significant odds ratio of 2 .8150 for cancer risk. Semaglutide trials have reported mixed results, with some studies showing an increase in neoplasm events in the intervention groups. Although GLP-1 receptor agonists effectively manage weight and glycemic control in overweight/obese patients, their association with increased cancer risk warrants cautious application, especially in individuals with a predisposition to thyroid or pancreatic cancers. Further studies are needed to conclusively determine the safety profile of these therapies.  \nCategories: Therapeutics, Oncology, Endocrinology/Diabetes/Metabolism  \nKeywords: cancer risk, glp-1 receptor agonists, liraglutide, obesity, semaglutide  \nIntroduction And Background  \nGlucagon-like peptide-1 (GLP-1) is a critical incretin hormone secreted after meals in healthy individuals. It plays a vital role in glucose homeostasis by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, reducing appetite, and potentially preventing β-cell apoptosis [1] . These effects have made GLP-1 receptor agonists (GLP-1RAs) a crucial therapeutic class for managing type 2 diabetes mellitus (T2DM) . GLP-1RAs are categorized into short-acting agents (e.g., exenatide, lixisenatide) and longacting formulations (e.g., albiglutide, dulaglutide, exenatide extended-release, and liraglutide) . The shortacting agents primarily affect postprandial glucose levels by inhibiting gastric emptying. In contra","cbCaiukulSnqqjoJ","https://ap.wps.com/l/cbCaiukulSnqqjoJ","pdf",2813827,15,"English","# Abstract\n# Introduction and Background\n# How to Cite This Article","[{\"question\":\"What is the document’s main research question about GLP-1 receptor agonists?\",\"answer\":\"It evaluates whether GLP-1 receptor agonists are associated with cancer incidence, with attention to pancreatic and thyroid cancers, in obese/overweight populations.\"},{\"question\":\"How were studies selected for the systematic review and meta-analysis?\",\"answer\":\"The review used a systematic search of PubMed, Scopus, and Cochrane to identify randomized clinical trials, followed by data extraction and risk-of-bias assessment using the Risk of Bias 2 tool.\"},{\"question\":\"What did the included randomized trials show regarding cancer risk and metabolic outcomes?\",\"answer\":\"Across nine included RCTs, GLP-1 receptor agonists reduced body weight and HbA1c in non-diabetic overweight/obese participants, but neoplasm incidences varied by agent; liraglutide showed a statistically significant odds ratio for cancer risk.\"}]","Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists - A Systematic Review and Meta-Analysis | PDF",1790179914,38,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/adde82372bea0edc048fe6342ad1e3e7.webp",983,1390,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64a93732b38b971119fabce4cfd1614d.webp",982,1389,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd163e4a5305cf77f98d2a79b5326716.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e6713f328a37229d1b8836dba44c67d.webp",980,1386]